Table 3.
Gender-stratified strength of association between statin administration and typical COVID-19 symptoms (n=358). Nonbinary participants (n=3) and those not reporting their gender (n=7) were not included in the analysis due to low numbers.
| Gender (n) | COVID-19 symptom, odds ratio estimate (95% CIa) | ||||||
|
|
Headache | Fever | Loss of smell or taste | Sore throat | Shortness of breath | Joint or muscle pain | Dry cough |
| Female (2250) |
0.3
b
(0.15-0.59) |
0.63 (0.15-2.61) |
0.85 (0.26-2.76) |
0.27
(0.12-0.61) |
1.28 (0.63-2.57) |
0.77 (0.38-1.53) |
0.84 (0.5-1.42) |
| Male (1394) |
0.58
(0.35-0.95) |
0.21 (0.03-1.58) |
0.68 (0.24-1.95) |
0.73 (0.44-1.2) |
1.23 (0.67-2.25) |
0.97 (0.59-1.6) |
0.65 (0.41-1.02) |
aLower and upper limits of 95% Wald confidence interval.
bItalic text indicates statistically significant values.